Authors : Ashwin Shajith; Aparna Salimon

Volume/Issue : Volume 11 - 2026, Issue 3 - March

Google Scholar : https://tinyurl.com/4vnhynes

Scribd : https://tinyurl.com/bddccuds

DOI : https://doi.org/10.38124/ijisrt/26mar441

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Chronic kidney disease is associated with a markedly increased risk of cardiovascular morbidity and mortality, even in the absence of obstructive coronary artery disease. Traditional cardiovascular risk factors do not fully explain the high burden of cardiac complications observed in patients with renal dysfunction, suggesting the involvement of additional pathophysiological mechanisms. Coronary microvascular dysfunction has emerged as a potential contributor to myocardial injury in chronic kidney disease. It refers to abnormalities in the coronary microcirculation that impair myocardial perfusion despite normal epicardial coronary arteries. Growing clinical and imaging evidence indicates that impaired coronary microvascular function may occur early in the course of chronic kidney disease. This review examines the relationship between coronary microvascular dysfunction and chronic kidney disease and explores the possibility that microvascular dysfunction may represent a preclinical stage in the development of uraemic cardiomyopathy. The paper discusses current clinical evidence, underlying mechanisms including endothelial dysfunction, inflammation, oxidative stress, uremic toxin accumulation, and neurohormonal activation, as well as available diagnostic approaches. Understanding the role of coronary microvascular dysfunction in chronic kidney disease may improve early cardiovascular risk assessment and support strategies aimed at preventing progression to structural myocardial remodeling.

Keywords : Coronary Microvascular Dysfunction; Chronic Kidney Disease; Uraemic Cardiomyopathy; Cardiorenal Syndrome; Endothelial Dysfunction; Myocardial Remodeling.

References :

1. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” N Engl J Med, vol. 351, pp. 1296-1305, 2004.
2. G. M. London, “Left ventricular alterations and end-stage renal disease,” Nephrol Dial Transplant, vol. 17, pp. 29-36, 2002.
3. K. Amann and E. Ritz, “The heart in renal failure: Morphological changes of the myocardium,” Nephrol Dial Transplant, vol. 13, pp. 1930-1938, 1998.
4. D. M. Charytan, H. R. Shelbert, and M. F. Di Carli, “Coronary microvascular function in early chronic kidney disease,” Circ Cardiovasc Imaging, vol. 3, pp. 663-671, 2010.
5. N. Koivuviita, R. Tertti, M. J. Jarvisalo, et al., “Increased myocardial perfusion heterogeneity in patients with chronic kidney disease,” J Am Soc Nephrol, vol. 20, pp. 2335-2342, 2009.
6. T. Kubo, A. Takahashi, N. Yamasaki, et al., “Coronary microvascular dysfunction and albuminuria in patients with chronic kidney disease,” Int J Cardiol, vol. 176, pp. 145-149, 2014.
7. V. R. Taqueti and M. F. Di Carli, “Coronary microvascular disease pathogenic mechanisms and therapeutic options,” J Am Coll Cardiol, vol. 72, pp. 2625-2641, 2018.
8. P. G. Camici and F. Crea, “Coronary microvascular dysfunction,” N Engl J Med, vol. 356, pp. 830-840, 2007.
9. A.R. Chade, D. Brosh, S. T. Higano, et al., “Mild renal insufficiency is associated with reduced coronary flow reserve,” Kidney Int, vol. 69, pp. 266-271, 2006.
10. E. Ritz and K. Amann, “Cardiac structure and function in chronic kidney disease,” Clin J Am Soc Nephrol, vol. 6, pp. 1526-1532, 2011.
11. Zoccali, F. A. Benedetto, F. Mallamaci, et al., “Prognostic value of echocardiographic indicators of left ventricular systolic function in dialysis patients,” J Am Soc Nephrol, vol. 15, pp. 1029-1037, 2004.
12. J. Rangaswami, V. Bhalla, J. E. Blair, et al., “Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies,” Circulation, vol. 139, pp. e840-e878, 2019.
13. W. J. Paulus and C. Tschope, “A novel paradigm for heart failure with preserved ejection fraction,” J Am Coll Cardiol, vol. 62, pp. 263-271, 2013.
14. K. Dharmashankar and M. E. Widlansky, “Vascular endothelial function and hypertension,” Curr Hypertens Rep, vol. 12, pp. 448-455, 2010.
15. R. Vanholder, E. Schepers, A. Pletinck, et al., “The uremic toxicity of indoxyl sulfate and p-cresyl sulfate,” J Am Soc Nephrol, vol. 25, pp. 1897-1907, 2014.
16. A. Herzog, R. W. Asinger, A. K. Berger, et al., “Cardiovascular disease in chronic kidney disease,” Kidney Int, vol. 80, pp. 572-586, 2011.
17. V. L. Murthy, M. Naya, C. R. Foster, et al., “Improved cardiac risk assessment with noninvasive measures of coronary flow reserve,” Circulation, vol. 124, pp. 2215-2224, 2011.
18. V. R. Taqueti, L. J. Shaw, N. R. Cook, et al., “Excess cardiovascular risk associated with impaired coronary flow reserve,” Circulation, vol. 135, pp. 566-577, 2017.
19. Ronco, M. Haapio, A. A. House, et al., “Cardiorenal syndrome,” J Am Coll Cardiol, vol. 52, pp. 1527-1539, 2008.
20. P. A. McCullough, S. Li, C. T. Jurkovitz, et al., “Chronic kidney disease and cardiovascular disease in high-risk population,” Am J Kidney Dis, vol. 51, pp. S38-S45, 2008.